Picture of Essex Bio-Technology logo

1061 — Essex Bio-Technology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Brief: Essex Bio-Technology's unit Receives Approval For Commercialisation Of Multi-Dose Sodium Hyaluronate Eye Drops From NMPA

Jan 9 (Reuters) - Essex Bio-Technology Ltd 1061.HK:

UNIT RECEIVES APPROVAL FOR MULTI-DOSE SODIUM HYALURONATE EYE DROPS FROM NMPA

RECEIVED APPROVAL FOR REGISTRATION & COMMERCIALISATION OF THE APPROVED PRODUCT

Further company coverage: 1061.HK

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Essex Bio-Technology

See all news